PhRMA Hill lobbying will be weakened by Nersesian departure, work environment investigation.

Executive Summary

PhRMA CAPITOL HILL LOBBYING WILL BE WEAKENED going into the crucial period for consideration of FDA reform. Two related events are likely to reduce the association's lobbying resources and to divert its attention from that task at the beginning of 1996. At the beginning of November, VP-Federal Legislation Lynda Nersesian announced her intention to leave the Pharmaceutical Research & Manufacturers of America at the end of the year. That resignation has precipitated an outside investigation of the work environment at the association and a distraction within the industry's Washington lobbying community.